Too expensive? Migraine treatments are controversial
Antibodies can be given for more severe headaches, but they are expensive. To what extent should their access be restricted?
It is estimated that more than one million people suffer from migraines in Switzerland. Monoclonal antibodies are intended for those who have particularly frequent and severe seizures, with the aim of preventing them.
Isabella Finzi
“This is the first time that patients have spoken to me about miracles,” exclaims Philippe Ryvlin, head of the department of clinical neuroscience at CHUV. The professor suggests a new family of migraine treatments. But these monoclonal antibodies are expensive and expensive report on medicine published on November 17, the insurance company Helsana warns against the risk of an explosion of costs.